Back to top

The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 12, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caladrius Biosciences, Inc. (Nasdaq:(CLBS - Free Report)  Free Report), Orexigen Therapeutics, Inc. (Nasdaq:(OREX - Free Report)  Free Report), Sangamo Therapeutics, Inc. (Nasdaq:(SGMO - Free Report)  Free Report) and Syndax Pharmaceuticals, Inc. (Nasdaq:(SNDX - Free Report)  Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

These 4 Biotech Stocks Likely to Keep Momentum

Within the Medical sector, biotech stocks have performed well so far this year. The pharma and biotech industry has demonstrated strength during the period despite challenges like rising competition, pipeline setbacks, slowdown in growth of mature products and generic competition for certain key drugs. Although drug pricing risk persists, investors are seemingly comfortable with the scenario and are focused on the fundamentals.

A lot of factors were responsible for the recovery of the sector this year and are expected to lead to its sustained recovery. These include new product sales ramp up, R&D success and innovation, strong clinical study results, regular FDA approvals and continued strong performance of legacy products. Moreover, tax reforms as well as cash repatriation supported the recovery as well.

The NASDAQ Biotechnology Index is up 26.1% YTD after sliding 19.1% in 2016.

In fact, the Zacks Medical-Biomed and Genetics sector is up 10.3% YTD, having outpaced the 8.3% gain for the S&P 500.

A Look at the Fundamentals

Despite the rally, it’s hard to find value in this space, as stocks with solid future prospects have already appreciated significantly. But as the momentum is likely to continue for some time, it’s a good idea to pick a few stocks that are unlikely to lose their momentum soon.  

4 Biotech Stocks to Buy Now

We have taken the help of the Zacks Stock Screener to select the stocks. To shortlist the stocks from the vast universe of biotech sector, we have picked stocks that carry a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a Momentum Score of A.

We have also taken into consideration a few more criteria to select the stocks. These include better returns than the industry this year, upward estimate revisions of more than 5% and average daily volume of more than 20,000. Our research shows that stocks with this combination offer the best upside potential.

Here are four stocks that fulfilled these criteria:

Caladrius Biosciences, Inc. (Nasdaq:(CLBS - Free Report) Free Report) is a biopharmaceutical company active in the field of stem cell therapy. It carries a Zacks Rank #2 (Buy). Shares of the company have gained 41% year to date, outperforming the 15.7% increase recorded by its industry. Also, the Zacks Consensus Estimate for 2018 has improved by 7.2% over the last 60 days.

Orexigen Therapeutics, Inc. (Nasdaq:(OREX - Free Report) Free Report) is a pharmaceutical company that is mainly associated with development of treatments for obesity. It carries a Zacks Rank of #2. Shares of the company have gained 32.8% year to date, outperforming the industry. Further, its Zacks Consensus Estimate for the current year has improved 6.1% over the last 60 days.

Sangamo Therapeutics, Inc. (Nasdaq:(SGMO - Free Report) Free Report) is a biopharmaceutical company associated with developing technologies in gene therapy. It also carries a Zacks Rank #2. Shares of the company have gained a massive 341% year to date, significantly outperforming the industry. In addition, the Zacks Consensus Estimate for the current year moved north by 8.6% and by 23.1% for 2018 over the last 60 days.

Syndax Pharmaceuticals, Inc. (Nasdaq:(SNDX - Free Report) Free Report) is a clinical stage biopharmaceutical company, which carries a Zacks Rank #2. Shares of the company have gained 74.1% year to date, outperforming the industry. Moreover, the Zacks Consensus Estimate for the current year and 2018 has improved 14.3% and 16%, respectively over the last 60 days.

You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on CLBS - FREE

Get the full Report on OREX - FREE

Get the full Report on SGMO - FREE

Get the full Report on SNDX - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like